HeartWare, based in Framingham, Mass., develops ventricular assist devices, which are surgical implants that copy the heart’s blood-pumping function.
The acquisition of HeartWare will expand Medtronic’s portfolio of diagnostic tools and therapies for patients with heart failure.
“[Medtronic’s] expansive expertise in the development of implantable systems and battery technologies, patient monitoring, manufacturing, global regulatory policy and commercialization should help accelerate the development and introduction of our innovative pipeline products, and will expand access to our therapies and offerings to the sizeable heart failure population,” said Doug Godshall, MBA, president and CEO of HeartWare, in a statement on the companies website.
The companies expect to close the deal in late October.
More articles on supply chain:
Medical device hacking on the rise
FDA approves new radiation therapy system
BMS’ bladder cancer drug granted breakthrough therapy designation
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
